Clinical trial · Observational
p-AKT Expression on Clinical Outcomes in Malignant Lymphoma
The Impact of Activated p-AKT Expression on Clinical Outcomes in Malignant Lymphoma : A Clinicopathological Study
NCT01789060CI-TRIAL-00009391completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
PI3K(phosphatidylinositol 3-kinase)/AKT pathway is an important oncogenic signaling pathway. However, clinical information about the significance of p-AKT expression in malignant lymphoma is not fully understood yet. In this study, we investigated the overexpression of p-AKT and its prognostic implication in malignant lymphoma.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Malignant Lymphoma | Lymphoma | ALIAS | 0.90 |
| P13K-AKT Pathway Deregulation | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| p-AKT immunohistochemical staining | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- p-AKT
- description
- p-AKT immunohistochemical staining,high p-AKT expression (upper quartile), low p-AKT expression (lower 3 quartiles)
- interventionNames
- Other: p-AKT immunohistochemical staining
Primary outcomes (1)
- measure
- Difference of overall survival according to p-AKT status in malignant lymphoma
- timeFrame
- study entry
Secondary outcomes (1)
- measure
- Subgroup analysis of overall survival according to histologic subtypes (GCB vs non GCB)
- timeFrame
- study entry
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 17 Years
- Maximum age
- 90 Years
Show eligibility criteria text
Inclusion Criteria: 1. the patients were pathologically confirmed of malignant lymphoma, according to the World Health Organization classification; 2. the patients had adequate paraffin-embedded biopsy specimen or unstained slides for immunostaining of p-AKT. Exclusion Criteria: 1\. Primary central nervous system lymphoma was excluded in this study
References
Publications (1)
- DERIVEDHong JY, Hong ME, Choi MK, Kim YS, Chang W, Maeng CH, Park S, Lee SJ, Do IG, Jo JS, Jung SH, Kim SJ, Ko YH, Kim WS. The impact of activated p-AKT expression on clinical outcomes in diffuse large B-cell lymphoma: a clinicopathological study of 262 cases. Ann Oncol. 2014 Jan;25(1):182-8. doi: 10.1093/annonc/mdt530. PMID 24356628